Depression: assessment and treatment
Depression is more than sadness: a persistent change in mood, energy and interest that affects sleep, thinking and daily functioning. It is a common and treatable illness: treatment depends on its severity and may combine psychotherapy, antidepressants, physical activity and better sleep.

One of the images most historically associated with melancholy. Depression, as it is understood today, is a treatable clinical condition.
Albrecht Dürer, Melencolia I, 1514. Engraving. The Metropolitan Museum of Art, New York. Public domain. Catalogue record (external site)
In brief
- Antidepressants take a few weeks to work and are continued for at least six months.
- Past periods of euphoria change treatment, as bipolar disorder often begins with depression.
- No response to two antidepressants means reviewing the diagnosis and planning the options in steps.
What it is
A depressive episode means low mood or loss of interest nearly every day for at least two weeks.
of adults in Portugal had major depression in the past year.
DGS, Mental Health in Numbers 2013.1
Read more
A depressive episode is diagnosed when depressed mood or loss of interest and pleasure in usual activities is present most of the day, nearly every day, for at least two weeks, together with other symptoms and with an impact on personal, family or working life.
It results from the interaction of biological, psychological and social factors. Physical illnesses, some medicines and alcohol use can cause or worsen it. The relationship with cardiovascular disease runs both ways: depression is associated with higher cardiovascular risk and is more common in people with heart disease.
Signs and symptoms
- Sadness, emptiness or irritability
- Loss of interest or pleasure
- Tiredness and lack of energy
- Sleep and appetite changes
- Poor concentration and indecision
- Slowing down or agitation
- Excessive guilt or worthlessness
- Thoughts of death or suicide
When to seek an assessment
- More than two weeks, affecting work, relationships or self-care.
- Symptoms that return after improvement.
- Treatment that is not working.
What the assessment involves
- Current and previous episodes, severity and risk.
- Blood tests, if needed, and medication review.
Read more
The psychiatric assessment characterises the current and previous episodes, their severity and risk, and looks for factors that would change treatment. One of the most important points is to find out whether there have been periods of euphoria, excessive energy or a reduced need for sleep, because bipolar disorder often begins with depressive episodes and is treated differently.
Depending on the case, blood tests may be requested (for example thyroid function, vitamin B12, full blood count) to rule out medical causes, and the medication the person already takes is reviewed.
Treatment
It depends on severity, history and preferences.
Mild depression
- Behavioural activation and exercise
- Cognitive behavioural therapy
Moderate to severe
- Antidepressant with psychotherapy: generally more effective
Over time
- Effect after a few weeks
- Continue for at least six months
- Stop gradually
Read more
- Mild depression: psychoeducation, behavioural activation, structured physical activity and psychotherapy (for example cognitive behavioural therapy) are first-line options.
- Moderate to severe depression: combining an antidepressant with psychotherapy is generally more effective than either alone.
Antidepressants usually take a few weeks to work. After improvement, continuing them for at least six months is recommended to reduce the risk of relapse; stopping should be gradual and supervised. Regularising sleep and treating associated physical illnesses are part of the plan.
For depression that does not respond to the usual treatments, the page on ketamine in treatment-resistant depression summarises what is approved and what is still being studied. The difference between the names is explained in the article ketamine and esketamine: what is the difference?
Treatment-resistant depression
It is depression that has not responded to at least two adequate antidepressants.
- Options in steps: Treatment-resistant depression and esketamine and ketamine.
Read more
Depression is considered treatment-resistant when it has not responded to at least two adequate antidepressants at a suitable dose and duration. Before changing strategy, the diagnosis, adherence and associated factors are reviewed, and the options are organised in steps, from optimising medication to neuromodulation.
The page Treatment-resistant depression explains the definition, the assessment and where each option fits; research with psychedelics is summarised in Psychedelics for depression.
In numbers
Depression in Portugal: past year and lifetime
- Major depression — past year6.8%
- All depressive disorders — past year7.9%
- All depressive disorders — lifetime19.3%
Read also
- Psychedelic-assisted therapy: what it is and how it is studied
- Ketamine and esketamine treatment for treatment-resistant depression
- Treatment-resistant depression: step-by-step options
- Psilocybin and other psychedelics for depression
- MDMA-assisted therapy for post-traumatic stress disorder
- Psychedelics for anxiety: LSD and psilocybin
Frequently asked questions
Are antidepressants addictive?
They do not cause dependence in the sense of addiction, and the dose does not need to be increased to maintain the effect. Stopping abruptly can cause discontinuation symptoms, which is why tapering should be gradual and supervised by the doctor.
References
- Directorate-General of Health (Portugal). Portugal: Mental Health in Numbers – 2013 [in Portuguese]. National Mental Health Programme. Lisbon: DGS; 2013. (Data from the National Mental Health Epidemiological Study, 2013.) Source (external site)
- Xavier M, Baptista H, Mendes JM, Magalhães P, Caldas-de-Almeida JM. Implementing the World Mental Health Survey Initiative in Portugal – rationale, design and fieldwork procedures. Int J Ment Health Syst. 2013;7:19. Source (external site)
- World Health Organization. Depressive disorder (depression) [fact sheet]. Geneva: WHO; 2026 [updated 2026 Sep 11]. Source (external site)
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). London: NICE; 2022. Source (external site)
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text revision (DSM-5-TR). Washington (DC): American Psychiatric Association Publishing; 2022. Source (external site)
- Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66. DOI (external site)
- GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-50. DOI (external site)
- Directorate-General of Health (Portugal). Depression and other common mental disorders: global and national context [in Portuguese]. Lisbon: DGS; 2017. Source (external site)
This page is for information only and does not replace an individual medical assessment.
Written and reviewed by Pedro Zuzarte, psychiatrist · Last reviewed:
A psychiatric assessment can be the first step.
If you are looking for psychedelic therapy, KETAMED is the clinic dedicated to this field.
Discover KETAMED (opens in a new tab)
Follow KETAMED: Instagram (opens in a new tab) · Facebook (opens in a new tab)